CANADIAN BURDEN OF CHOROIDAL NEOVASCULARIZATION SECONDARY TO PATHOLOGIC MYOPIA: FINAL RESULTS

被引：0
|
作者：
Zaour, N. [1 ]
Heisel, O. [2 ]
Leteneux, C. [3 ]
Ma, P. [4 ]
机构：
[1] Novartis Pharmaceut Canada Inc, Dorval, PQ, Canada
[2] Syreon Corp, Vancouver, BC, Canada
[3] Novartis Pharma AG, Basel, Switzerland
[4] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 03期
关键词：
D O I：
10.1016/j.jval.2014.03.1657
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PSS10
引用
收藏
页码：A284 / A285
页数：2
相关论文
共 50 条
  • [31] Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia - 1-year results of a prospective series
    Lam, DSC
    Liu, DTL
    Fan, DSP
    Lai, WW
    So, SF
    Chan, WM
    EYE, 2005, 19 (08) : 834 - 840
  • [32] Photodynamic therapy with verteporfin for juxtafoveal choroidal neovascularization secondary to pathologic myopia—1-year results of a prospective series
    D S C Lam
    D T L Liu
    D S P Fan
    W W Lai
    S F So
    W-M Chan
    Eye, 2005, 19 : 834 - 840
  • [33] LONG-TERM RESULTS OF PHOTODYNAMIC THERAPY FOR SUBFOVEAL CHOROIDAL NEOVASCULARIZATION WITH PATHOLOGIC MYOPIA
    Giansanti, Fabrizio
    Virgili, Gianni
    Donati, Maria Carla
    Giuntoli, Matteo
    Pieretti, Giulia
    Abbruzzese, Giacomo
    Menchini, Ugo
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2012, 32 (08): : 1547 - 1552
  • [34] Choroidal neovascularization in pathologic myopia: Three-year results after photodynamic therapy
    Krebs, I
    Binder, S
    Stolba, U
    Glittenberg, C
    Brannath, W
    Goll, A
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2005, 140 (03) : 416 - 425
  • [35] Intravitreal Bevacizumab Treatment for Choroidal Neovascularization in Pathologic Myopia: 12-month Results
    Gharbiya, Magda
    Allievi, Francesca
    Mazzeo, Luigi
    Gabrieli, Corrado Balacco
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2009, 147 (01) : 84 - 93
  • [36] Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years?
    Bogomil Voykov
    Faik Gelisken
    Werner Inhoffen
    Michael Voelker
    Karl Ulrich Bartz-Schmidt
    Focke Ziemssen
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2010, 248 : 543 - 550
  • [37] Bevacizumab for choroidal neovascularization secondary to pathologic myopia: Is there a decline of the treatment efficacy after 2 years?
    Voykov, Bogomil
    Gelisken, Faik
    Inhoffen, Werner
    Voelker, Michael
    Bartz-Schmidt, Karl Ulrich
    Ziemssen, Focke
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2010, 248 (04) : 543 - 550
  • [38] Choroidal neovascularization in pathologic myopia: Recent developments in diagnosis and treatment
    Soubrane, Gisele
    SURVEY OF OPHTHALMOLOGY, 2008, 53 (02) : 121 - 138
  • [39] Choroidal neovascularization and coincident perforating scleral vessels in pathologic myopia
    Giuffre, Chiara
    Querques, Lea
    Carnevali, Adriano
    De Vitis, Luigi A.
    Bandello, Francesco
    Querques, Giuseppe
    EUROPEAN JOURNAL OF OPHTHALMOLOGY, 2017, 27 (02) : E39 - E45
  • [40] Epidemiology and Disease Burden of Pathologic Myopia and Myopic Choroidal Neovascularization: An Evidence-Based Systematic Review
    Wong, Tien Y.
    Ferreira, Alberto
    Hughes, Rowena
    Carter, Gemma
    Mitchell, Paul
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2014, 157 (01) : 9 - 25
12345